Summit Therapeutics (SMMT) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Summit Therapeutics (SMMT) over the last 9 years, with Q3 2025 value amounting to $234.2 million.
- Summit Therapeutics' Operating Expenses rose 30119.74% to $234.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $935.4 million, marking a year-over-year increase of 37538.33%. This contributed to the annual value of $226.3 million for FY2024, which is 6293.94% down from last year.
- As of Q3 2025, Summit Therapeutics' Operating Expenses stood at $234.2 million, which was up 30119.74% from $568.4 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Operating Expenses registered a high of $568.4 million during Q2 2025, and its lowest value of $20.8 million during Q3 2023.
- Moreover, its 4-year median value for Operating Expenses was $58.4 million (2024), whereas its average is $108.8 million.
- Per our database at Business Quant, Summit Therapeutics' Operating Expenses crashed by 824.42% in 2023 and then skyrocketed by 85348.14% in 2025.
- Summit Therapeutics' Operating Expenses (Quarter) stood at $21.4 million in 2022, then surged by 69.79% to $36.4 million in 2023, then surged by 81.17% to $65.9 million in 2024, then skyrocketed by 255.26% to $234.2 million in 2025.
- Its Operating Expenses stands at $234.2 million for Q3 2025, versus $568.4 million for Q2 2025 and $66.9 million for Q1 2025.